Use of organic compounds in the treatment of disease

摘要

The use of a dry powder comprising (A) formoterol, or a pharmaceutically acceptable salt or solvate thereof, and (B) a pharmaceutically acceptable particulate diluent or carrier, such as lactose, in an amount of from 400 ìg to 5000 ìg per ìg of (A) for the preparation of an inhalable medicament for the treatment of chronic obstructive pulmonary disease.